BNET Industries
Allergan Inc. (AGN) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $3.9B
- Profit
- Dec 31 2007
- $499.3M
- Market Cap
- Aug 27 2008
- $17.2B
Latest News and Analysis
Allergan: When Deals Get Ugly
Eben Tessari submits: What’s a billion between friends? The University of Georgia Research Foundation Inc. has filed suit claiming Allergan AGN screwed them out of a couple hundred million bucks for a drug that’s earned the company more than a billion dollars. by Eben Tessari
FTC Antitrust Chief Leaving For Law Firm
WASHINGTON (Reuters) - The antitrust chief at the U.S. Federal Trade Commission is leaving after a 2-1/2 year period that saw the agency open a formal investigation into Intel Corp INTC and try to stop the merger of two organic grocery ...
Allergan Inc. Q2 2008 Earnings Call Transcript
Allergan Inc. AGN Q2 2008 Earnings Call
Zacks Analyst Blog Highlights: Lithia Motors, Ford, General Motors, Inspire Pharmaceuticals and Allergan Pharmaceuticals
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lithia Motors, Inc. (NYSE: LAD), Ford (NYSE: F), General Motors (NYSE:...
Allergan Announces Agreement to Acquire Aczone® Gel 5%
- - Acquisition Will Address Unmet Medical Need in Acne Therapies and Strengthen Allergan's Medical Dermatology Product Portfolio - -
QLT announces agreement to sell Aczone® to Allergan for approximately US$150 million
VANCOUVER, June 9 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that QLT USA, Inc., its wholly-owned subsidiary, has entered into an asset purchase agreement with Allergan Sales, LLC, a wholly-owned subsidiary of Allergan, Inc. to fully divest QLT's worldwide rights to AczoneR, a prescription topical...
Allergan Announces Intent to File New Drug Application for Bimatoprost as Novel Treatment to Stimulate Natural Eyelash Growth
IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) announced today that it intends to file a New Drug Application by end of the third quarter of 2008 with the U.S. Food and Drug Administration FDA for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth. Allergan has completed its...
Economic Concerns Weighing Down Allergan
HEALTHCARE: Implants boost cosmetic sales, small part of unit
Allergan, Inc. Q1 2008 Earnings Call Transcript
Allergan, Inc. Q1 2008 Earnings Call Transcript
Allergan Reports First Quarter 2008 Operating Results
* Total Product Net Sales Increased 23 Percent for the First Quarter
Allergan Passes Pfizer Acquisition Test, Analyst Says
Valeant Upbeat on Liver Drug, Analyst Unfazed; Spectrum Bone Cancer Drug Gets FDA OK
Allergan Comments on the United States Department of Justice Subpoena for the Production of Documents Relating to Promotional Practices of BOTOX® for Therapeutic Uses
IRVINE, Calif. -- Allergan, Inc. (NYSE: AGN) today announced that it received a subpoena from the United States Department of Justice, United States Attorney's Office for the Northern District of Georgia requesting the production of documents regarding promotional practices involving BOTOX([R]) botulinum toxin type A for therapeutic indications.
Allergan awards Botox DTC to Pacific
ALLERGAN AWARDED Pacific Communications the DTC assignment for its severe axillary hyperhidrosis severe underarm sweating indication on Botox following a competitive pitch.
Research and Markets: Allergan Inc. Company Profile Examines the Companys Key Business Structure and Operations History and Products
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c84281) has announced the addition of "Allergan, Inc. Company Profile" to their offering.
Allergan: Familiar Strategy in Handling Botox News
Grubb & Ellis Buys Five Medical Office Buildings in Kansas, Florida; Avanir Narrows Loss
Chance Meeting With Clinique President Drove Allergan Deal
Botox Rival's FDA Snag Could Delay Launch; Analyst Likes Local Nursing Home Companies
Commenting on the U.S. Food and Drug Administration Early Communication, Allergan Clarifies FDA's Inquiry Relates Primarily to High Dose Medical Uses of BOTOX®, Rather Than BOTOX® Cosmetic for Aesthetic Use
IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) today commented on and provided support for the U.S. Food and Drug Administration's FDA "Early Communication" regarding a safety review of botulinum toxins in the United States.
Clinique to develop skin care line with Allergan.(INTERNATIONAL NEWS)
Estee Lauder's skin care brand Clinique has signed a deal with speciality pharmaceutical company Allergan to create a line of products for doctors' offices. Estee Lauder's skin care brand Clinique has signed a deal with speciality pharmaceutical company Allergan to create a line of...
First Allergan's Cautious Outlook Roils, Then Downplayed as 'Under Promising'
A strikingly conservative first-quarter forecast from Allergan Inc. had analysts reading tea leaves last week to discern what's going on at the Irvine drug maker.
Clinique, Allergan collaborate for physician skin care line.(Industry News)
Clinique Laboratories, LLC has collaborated with global medical aesthetics company Allergan, Inc. on a new skin care line to be sold exclusively in U.S. physicians' offices. The range is expected to launch in the fall of 2008. Clinique Laboratories, LLC has collaborated with global...
- Next »
- page 1 of 21
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- board (26 results)
- FDA (24 results)
- board of directors (15 results)
- agreement (14 results)
- Botox (12 results)
- collaboration (12 results)
- acquisition (10 results)
- Marketing (10 results)
- earnings per share (8 results)
- merger (6 results)
- R&D (6 results)
- health care (6 results)
- Orange PCS (5 results)
- dividend (5 results)
- blog (5 results)
- sales (4 results)
- S&P 500 (4 results)
- New York Stock Exchange (4 results)
- Fitch (4 results)
- Company (3 results)
- licensing agreement (3 results)
- patient (3 results)
- stock (3 results)
- asset (3 results)
- Manufacturing (3 results)
- strategy (3 results)
- Pfizer Inc. (3 results)
- vision (3 results)
- Call Transcript (3 results)
- layoff (3 results)
- Earnings (3 results)
- Seeking Alpha (3 results)
- Microsoft Outlook (3 results)
- Financial Accounting (3 results)
- Finance (3 results)
- Incorporated: 1948
- CEO: Mr. David E.I. Pyott
Allergan is a health care company that develops and markets specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological and other specialty markets. Co. targets products and technologies related to specific disease areas such as glaucoma, retinal disease, dry eye, psoriasis, acne, movement disorders, neuropathic pain and genitourinary diseases. Co.'s products are sold to, among others, drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, hospitals and ambulatory surgery centers.
Key Competitors
Allergan Inc. Company Info
Board of Directors
Mr. David E.I. Pyott
Chairman
Mr. Leonard D. Schaeffer
Mr. Robert A. Ingram
Mr. Rusell T. Ray
Mr. Gavin S. Herbert
Chairman Emeritus
Dr. Herbert W. Boyer Ph.D.
Vice-Chairman
Dr. Deborah Dunsire M.D.
Prof. Trevor M. Jones Ph.D.
Mr. Louis J. Lavigne Jr.
Ms. Dawn Hudson
Mr. Michael R. Gallagher
Dr. Stephen J. Ryan M.D.
Contact Information
2525 Dupont Drive
P.O. Box 19534
Irvine, CA
714 246-4500
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
